Monitor KOMZIFTI prescription growth trajectory and new account expansion in coming quarters; watch for darlifarnib registrational study initiation in 1H 2027 and ASH 2026 presentations for ziftomenib combination data.
Drugs in focus
KURA drug pipeline →darlifarnib
● Neutral Named in this press release- Impact
- Phase
- Phase 1
- Time to market
- Likely 4-6+ years if successful; still in Phase 1 with registrational Phase 3 planned for 2028 at the earliest
- Next catalyst
- None dated
What to watchInvestors should watch the KCRS 2026 oral presentation on July 24 and the virtual investor call on July 27 for updated long-term Phase 1a durability data in ccRCC. The program is too early for binary positioning, the real value inflection points (Phase 1b randomization data, Phase 3 start in 2028, and the daraxonrasib combo entering the clinic in early 2027) are 12+ months away. KURA is a multi-asset company with an approved product, so darlifarnib is one of several value drivers.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $7.73entry
- T+1 · 5d ago −3.88%α −3.53% · $7.43
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kura Oncology reported Q3 2026 results with KOMZIFTI net product revenue of $13.9M, up 53% sequentially, and a net loss of $70.2M ($0.78 per share) versus consensus EPS of -$0.81. The company also announced FDA alignment on a darlifarnib registrational study and a $300M Oberland Capital financing facility.
Key Financial Metrics
Key Facts
- KOMZIFTI net product revenue $13.9M in Q3 2026, up 53% from Q2 2026
- Net loss $70.2M ($0.78 per share) vs consensus EPS -$0.81
- Total revenue $22.8M (product $13.9M + collaboration $8.9M)
- Cash and investments $492.1M as of Sep 30, 2026
- FDA alignment on ~40-patient darlifarnib monotherapy registrational study in HRAS-mutant salivary gland cancer
- Oberland Capital financing agreement provides up to $300M in potential funding
- Collaboration revenue guidance updated to $40M-$45M for 2026
- Eight ziftomenib abstracts accepted at ASH 2026 including two oral presentations
Financial Impact
KOMZIFTI product revenue $13.9M; net loss $70.2M; cash $492.1M; collaboration revenue guidance $40M-$45M for 2026
Risk Factors
- KOMZIFTI differentiation syndrome boxed warning and safety profile may limit commercial uptake
- Cash burn rate remains high with $492.1M cash vs $667.2M at year-end 2025
- Darlifarnib registrational study is early-stage with regulatory and enrollment risks
- Collaboration revenue declining ($8.9M vs $20.8M year ago) and guidance lowered
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3400190 |
Track record
29 reports on KURA
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 14 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Viewing Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers